4.5 Advanced Biologics, Cellular/Tissue Products (CTPs), & HBOT

Advanced Biologics, Cellular/Tissue Products (CTPs), & HBOT

When chronic wounds fail to achieve expected healing trajectories despite 4 weeks of optimal standard wound care, advanced therapeutic modalities are indicated. Cellular and Tissue-based Products (CTPs, historically termed skin substitutes) and Hyperbaric Oxygen Therapy (HBOT) represent advanced biological and physiological interventions designed to overcome stalled cellular signaling, severe hypoxia, and extracellular matrix (ECM) breakdown.

---

Cellular and Tissue-Based Products (CTPs)

CTPs are biological constructs applied to clean, full-thickness wounds to supply extracellular matrix scaffolding, growth factors, structural proteins (collagen types I, III, IV, VII), and bio-instructive signals that recruit host keratinocytes and fibroblasts to close the wound.

Classification of CTPs

1. Human Allografts: Derived from donated human tissue. Includes decellularized human dermis (e.g., AlloDerm) and human amniotic/chorionic membrane matrices (e.g., Epifix). Amniotic matrices contain rich concentrations of microRNA, hyaluronic acid, and anti-inflammatory cytokines.
2. Xenografts: Derived from non-human animal tissue. Includes bovine, porcine, or equine acellular dermal matrices (e.g., Oasis, PriMatrix) engineered to provide structural collagen scaffolding.
3. Bioengineered / Living Cell Constructs: Synthesized living tissue constructs containing living human keratinocytes and fibroblasts suspended within a bovine collagen or polyglactin mesh matrix (e.g., Apligraf, Dermagraft). Living cells actively secrete vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and transforming growth factor-beta (TGF-β).

Prerequisites & Qualification Criteria for CTP Application

Before applying an expensive CTP, stringent clinical criteria must be met:

• Standard Care Benchmark: The wound must have failed to achieve > 50% wound area reduction after 4 consecutive weeks of standard therapy (debridement, moist wound healing, off-loading, or compression).
• Wound Bed Preparation: The wound bed must be 100% clean and granulating, completely free of eschar, necrotic slough, foreign material, or uncontrolled exudate.
• Absence of Infection: Complete absence of local or systemic clinical infection, cellulitis, or active osteomyelitis.
• Vascular Perfusion Requirements: Adequate macrovascular perfusion must be verified: ABI ≥ 0.70, TBI ≥ 0.60, or TcPO2 > 30 mmHg.

Surgical Application Technique

1. Preparation: Debride wound margins to clean, bleeding tissue; achieve strict micro-hemostasis.
2. Placement & Fixation: Meshed or trimmed CTP is hydrated (if meshed/lyophilized) and placed directly over the wound bed ensuring zero air gaps. Secure borders with steri-strips, surgical staples, or non-absorbable sutures.
3. Secondary Dressing: Cover with a non-adherent primary contact layer (e.g., silicone mesh), followed by a protective secondary absorbent dressing. Keep undisturbed for 3 to 7 days.

---

Hyperbaric Oxygen Therapy (HBOT)

Hyperbaric Oxygen Therapy is a systemic medical treatment in which a patient breathes 100% pure oxygen under increased atmospheric pressure inside a sealed monoplace or multiplace hyperbaric chamber.

Physiological Mechanisms of HBOT

Under normal atmospheric conditions (1.0 ATA), arterial oxygen is carried almost exclusively bound to hemoglobin ($SaO_2 \approx 98%$), with only 0.3 mL O2 dissolved per 100 mL plasma. During HBOT at 2.0 to 2.5 ATA, Henry's Law dictates that dissolved plasma oxygen increases 10- to 20-fold (reaching 5.0 to 6.0 mL O2 per 100 mL plasma), achieving arterial oxygen tension ($PaO_2$) exceeding 1500 to 2000 mmHg.

This extreme hyperoxia triggers vital therapeutic responses:

• Angiogenesis: Hyperbaric oxygen creates a steep tissue-to-wound oxygen gradient that upregulates VEGF, stimulating capillary sprouting into hypoxic tissue.
• Leukocyte Bactericidal Enhancement: Neutrophil oxidative killing of phagocytosed bacteria requires oxygen; HBOT restores polymorphonuclear leukocyte bactericidal capacity in ischemic/diabetic tissue.
• Fibroblast Proliferation & Collagen Synthesis: Fibroblasts require a minimum $PO_2 > 30\text{ mmHg}$ to synthesize collagen matrices.
• Osteoclast Stimulation: Enhances bony remodeling to clear necrotic bone in osteomyelitis.

Approved Wound Indications for HBOT

CMS and the Undersea & Hyperbaric Medical Society (UHMS) approve HBOT for specific refractory wound conditions:

1. Diabetic Foot Ulcer (Wagner Grade 3, 4, or 5): Deep ulceration involving bone, tendon, or abscess that has failed standard therapy for 30+ days.
2. Chronic Refractory Osteomyelitis: Bone infection persisting despite surgical debridement and 4 to 6 weeks of targeted parenteral antibiotic therapy.
3. Soft Tissue Radionecrosis & Osteoradionecrosis: Radiation-induced tissue microvascular endarteritis and fibrosis.
4. Compromised Skin Flaps and Grafts: Acute ischemia in newly reconstructed surgical tissue.
5. Crush Injury & Acute Traumatic Ischemias

Treatment Protocols, Contraindications, & Complications

• Treatment Protocol: Standard regimen consists of 30 to 40 sessions (dives) administered 5 days per week. Each dive lasts 90 to 120 minutes at 2.0 to 2.5 ATA, incorporating short 'air breaks' (breathing room air for 5 minutes every 30 minutes) to prevent oxygen toxicity.
• Absolute Contraindication: Untreated Pneumothorax! Gas expansion inside an untreated pneumothorax during chamber decompression causes rapid tension pneumothorax and fatal cardiac arrest.
• Relative Contraindications: Severe bullous lung disease, upper respiratory infection, history of optic neuritis, severe claustrophobia, uncontrolled high fever.
• Complications: Aural barotrauma (tympanic membrane rupture), sinus barotrauma, central nervous system (CNS) oxygen toxicity (grand mal seizures), temporary visual myopia.